Mode
Text Size
Log in / Sign up

Intravenous magnesium sulfate serves as secondary adjunctive therapy for severe refractory acute asthma exacerbationsDoctors clarify when to use magnesium for severe asthma attacks

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Reserve intravenous magnesium as a secondary adjunctive therapy for severe asthma cases refractory to first-line treatment.

This umbrella review evaluates the efficacy and safety of intravenous versus nebulized magnesium sulfate in patients with acute asthma exacerbations. The scope includes an overview of systematic reviews and meta-analyses to determine the appropriate clinical role for both administration routes.

The authors conclude that intravenous magnesium sulfate is not intended for routine use but serves as a secondary adjunctive therapy specifically for severe cases refractory to first-line treatment. Regarding nebulized magnesium sulfate, the evidence does not support its routine use or as a replacement for first-line medications. The review notes that nebulized magnesium sulfate has a weak recommendation for patients who fail standard therapy.

A significant limitation noted by the authors is the overlap among primary studies, with a corrected covered area of 5.168%. The certainty of evidence varies considerably; GRADE analysis identified 13 high-quality outcomes, but also included 38 moderate-quality, 27 low-quality, and 26 extremely low-quality outcomes. Clinical application is limited to using intravenous magnesium as an adjunct in severe cases and nebulized magnesium only when standard therapies fail.

How this fits prior evidence

This umbrella review addresses a gap in the management of acute asthma exacerbations by clarifying the roles of magnesium sulfate administration routes. While previous coverage has focused on predictive risk scores, dietary impacts, medication adherence systems, and specific biologics like depemokimab for asthma, this evidence specifically clarifies the secondary adjunctive role of intravenous magnesium in severe cases.

When someone suffers from a severe asthma attack, every minute counts. Doctors sometimes consider using magnesium sulfate to help open up airways. However, there has been some confusion about how and when this medication should actually be used in an emergency.

This review of multiple studies looked at two ways to give the medicine: through an IV (intravenous) or through a breathing mask (nebulized). The findings show that neither method is a first choice for everyone. Instead, both methods are reserved as backup treatments for patients who do not respond well to standard first-line medications.

For those with severe cases that are hard to treat, the IV route is used as a secondary addition. For others, the nebulized version has a weak recommendation only when standard therapies fail. Because of these specific roles, magnesium is not meant for routine use and cannot replace the primary medicines doctors usually give first.

What this means for you:
Magnesium sulfate is a backup treatment for severe asthma, not a replacement for standard first-line medications.

Common questions

Is magnesium sulfate a standard treatment for asthma?

No, it is not intended for routine use. Doctors use it as a secondary adjunctive therapy only for severe cases of asthma that do not respond to first-line treatments. It is not a replacement for the primary medications usually given during an attack.

What is the difference between intravenous and nebulized magnesium?

Both methods are used as backup options rather than first choices. Intravenous magnesium is used for severe cases that are hard to treat, while nebulized magnesium has a weak recommendation for patients who fail standard therapy.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
This study aimed to conduct an umbrella review comparing intravenous versus nebulized magnesium sulfate for acute asthma exacerbations, providing evidence to guide route selection and clinical decision-making. We systematically searched PubMed, Embase, Cochrane Library, Web of Science, CNKI, VIP, WANFANG, and CBM from inception to August 2025, for systematic reviews/meta analyses comparing intravenous versus nebulized magnesium sulfate for acute asthma exacerbations. Overlap among primary studies was assessed using a citation matrix and corrected covered area. Quality assessment was performed using ROBIS, AMSTAR-2, PRISMA 2020, and GRADE. Quantitative and qualitative analyses of primary outcomes were performed. A total of 18 systematic reviews/meta analyses were included. The corrected covered area was 5.168%, indicating some overlap in primary studies. ROBIS judged all studies at low risk of bias. AMSTAR-2 rated 6 studies as high quality, 2 as moderate, and 10 as low. PRISMA 2020 scores ranged from 25.5 to 41, with 10 studies of high and 8 of moderate reporting quality. GRADE yielded 13 high-quality, 38 moderate-quality, 27 low-quality, and 26 extremely low-quality outcomes. This overview clarifies the role of intravenous magnesium sulfate in acute asthma: not for routine use but as secondary adjunctive therapy for severe cases refractory to first-line treatment. The role of nebulized magnesium sulfate is more complex—neither universally applicable nor a replacement for first-line medications. Current evidence does not support routine use, warranting only a weak recommendation for patients who fail standard therapy. Future research should focus on its synergistic effects with other therapies and further elucidate its mechanisms. https://www.crd.york.ac.uk/PROSPERO/, PROSPERO: CRD420251122150.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.